Prostate Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement
Authors:
- Matthew J. ResnickMRMatthew J. Resnick
- Christina LacchettiCLChristina Lacchetti
- Jonathan BergmanJBJonathan Bergman
- Ralph J. HaukeRHRalph J. Hauke
- Karen E. HoffmanKHKaren E. Hoffman
- Terrence M. KungelTKTerrence M. Kungel
- Alicia K. MorgansAMAlicia K. Morgans
- David F. PensonDPDavid F. Penson
- 20 March 2015
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (9) , 1078-1085
Abstract
Purpose: The guideline aims to optimize health and quality of life for the post-treatment prostate cancer survivor by comprehensively addressing components of follow-up care, including health promotion, prostate cancer surveillance, screening for new cancers, long-term and late functional effects of the disease and its treatment, psychosocial issues, and coordination of care between the survivor's primary care physician and prostate cancer specialist. Methods: The American Cancer Society (ACS) Prostate Cancer Survivorship Care Guidelines were reviewed for developmental rigor by methodologists. The American Society of Clinical Oncology (ASCO) Endorsement Panel reviewed the content and recommendations, offering modifications and/or qualifying statements when deemed necessary. Results: The ASCO Endorsement Panel determined that the recommendations from the 2014 ACS Prostate Cancer Survivorship Care Guidelines are clear, thorough, and relevant, despite the limited availability of high-quality evidence to support many of the recommendations. ASCO endorses the ACS Prostate Cancer Survivorship Care Guidelines, with a number of qualifying statements and modifications. Recommendations: Assess information needs related to prostate cancer, prostate cancer treatment, adverse effects, and other health concerns and provide or refer survivors to appropriate resources. Measure prostate-specific antigen (PSA) level every 6 to 12 months for the first 5 years and then annually, considering more frequent evaluation in men at high risk for recurrence and in candidates for salvage therapy. Refer survivors with elevated or increasing PSA levels back to their primary treating physician for evaluation and management. Adhere to ACS guidelines for the early detection of cancer. Assess and manage physical and psychosocial effects of prostate cancer and its treatment. Annually assess for the presence of long-term or late effects of prostate cancer and its treatment.Keywords
This publication has 25 references indexed in Scilit:
- Cancer Survivors in the United States: Prevalence across the Survivorship Trajectory and Implications for CareCancer Epidemiology, Biomarkers & Prevention, 2013
- Secondary malignancies following radiotherapy for prostate cancerTherapeutic Advances in Urology, 2010
- The Rate of Secondary Malignancies After Radical Prostatectomy Versus External Beam Radiation Therapy for Localized Prostate Cancer: A Population-Based Study on 17,845 PatientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Second Primary Cancer Risk of Radiation Therapy After Radical Prostatectomy for Prostate Cancer: An Analysis of SEER DataUrology, 2009
- Bladder cancer in cancer patients: population-based estimates from a large Swedish studyBritish Journal of Cancer, 2009
- Prostate Cancer–Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen EraJournal of Clinical Oncology, 2009
- Radiation Therapy for Prostate Cancer Increases Subsequent Risk of Bladder and Rectal Cancer: A Population Based Cohort StudyJournal of Urology, 2008
- Cancer incidence after localized therapy for prostate cancerCancer, 2006
- Preoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical ProstatectomyJNCI: Journal of the National Cancer Institute, 2006
- THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CANCER OF THE PROSTATE RISK ASSESSMENT SCORE: A STRAIGHTFORWARD AND RELIABLE PREOPERATIVE PREDICTOR OF DISEASE RECURRENCE AFTER RADICAL PROSTATECTOMYJournal of Urology, 2005